



**Contacts:**

Matt Niloff  
Senior Product Director  
Xcellerex, Inc.  
508-683-2296

**Parrish Galliher to be featured speaker  
on three expert panels at BIO 2008**

*Topics cover emerging technologies for  
biologics and vaccine production.*

**Marlborough, MA, May 6, 2008** – Xcellerex, Inc. announced today that Parrish Galliher, the company's founder and Chief Technology Officer, will be a featured speaker on three expert panels at the **BIO 2008** International Convention, to be held in San Diego on June 17-20, 2008.

With more than 25 years experience designing and operating biomanufacturing operations, Mr. Galliher has emerged as a leading voice in the design and practical application of disposables-based technologies that are enabling a shift in how biologics and vaccines are commercialized.

Details on the panels are provided below:

**Panel 1: Is Biomanufacturing the Next Product-Enabling Technology?**

This panel will be chaired by Robert Tenerowicz, Vice President of Operations for XOMA, Ltd. and will be held Friday, June 20 at 10:30 AM in room 29B.

**Description:** Since its inception, the biotechnology industry has depended on new technologies for the discovery and development of products. Manufacturing, although essential, has been positioned as a step in the commercialization process. With rapid growth in the number of biopharmaceutical products on the market and the advent of follow-on biologics, however, manufacturing is becoming a strategic, enabling technology that is allowing innovative companies with high-efficiency expertise to participate in product development. This panel will look at a number of companies that are leveraging unique manufacturing expertise to develop biopharmaceuticals and their product development strategies.

**- more-**

**Objectives:**

1. Explore how biotech manufacturing has become a product enabling technology.
2. Examine how manufacturing has become an integral part of product development.
3. Explain how to leverage manufacturing expertise as a competitive advantage.

**Panel 2: Moore's Law for Biomanufacturing: Innovation in a Maturing Biologicals Industry**

This panel will be chaired by Michael Kowolenko Ph.D, Senior Vice President, Biotech Operating Unit, TO&PS at Wyeth Pharmaceuticals, Inc., and will be held on Thursday, June 19 at 4:00 PM in room 29 B.

**Description:** Biotherapeutics are today the fastest-growing segment of the pharmaceutical industry, with more than 200 marketed products and hundreds more in development. This growth has created new demands for innovation in manufacturing: increased production efficiency, improved flexibility to make multiple products, reduced product development lead time and higher returns on manufacturing investment. This panel will examine a range of innovative biomanufacturing solutions, including new process development approaches, new expression systems and single-use disposable biomanufacturing systems.

**Objectives:**

1. Describe ongoing innovation in the manufacture of biologicals.
2. Explain the role of manufacturing innovation in driving and responding to growth in the sector.
3. Provide real-world examples of how biomanufacturers are making better biologicals and improving industry ROIs.

**Panel 3: Vaccine Renaissance**

This panel will be chaired by Cole Werble, Editor-in-Chief of the Windhover RPM Report and will be held on Thursday, June 19 at 8:30 AM in room 29A.

**Description:** If one word described the vaccine industry during the last decades of the 20th century, it was "shrinking." The perception of the business as a low-growth, low-margin business, fraught with manufacturing challenges and liability risks as well as the siren song of chronic therapeutics, discouraged new entrants and drove many companies in other directions. Today, the landscape has changed dramatically. Major pharmaceutical companies and startups are jumping back in, driven by scientific advances, demonstrated success with innovative, high-value products and increasing awareness of public health threats such as pandemic influenza. This session will explore some of the exciting areas of vaccine development and what this revitalized public and commercial interest means for global public health.

- more -

## **Objectives:**

1. Explore forces driving the re-ignited interest in vaccine development and business.
2. Detail the exciting advancements in vaccine development.
3. Look broadly at how this renewed public/commercial interest will affect global health.

**# # #**

## **About Xcellerex, Inc.**

Xcellerex is built around a unique biomanufacturing platform that features the innovative application of single-use component technology. Xcellerex offers a suite of world-class products and services to support the adoption of its platform. These include the XDR line of GMP single-use bioreactors, PDMax™ high-throughput process development and optimization services, and proven GMP manufacturing operated by an experienced CMC team. The company also actively seeks creative partnerships to facilitate access to the platform. Learn more at [www.xcellerex.com](http://www.xcellerex.com)

## **XCELLEREX SPEAKER BIOGRAPHY**

### **Parrish Galliher**

#### **Founder and Chief Technology Officer**

Mr. Galliher earned his BA in Biology at Boston University (1975). After 3 years as an EIT at Dynatech R/D Corp., he began graduate studies at MIT and earned his MS in Biochemical Engineering. Mr. Galliher joined Biogen, Inc. in 1981 where he was responsible for design, commissioning and management of Biogen's first biomanufacturing facility. He held various management positions in Process Development, Engineering and Clinical Manufacturing of biopharmaceuticals using bacteria, yeast and mammalian cells. As Director of Process Engineering, he led the team responsible for startup, initial validation and commissioning of Biogen's Avonex manufacturing facility licensed by the FDA in 1996. Mr. Galliher joined Alpha-Beta Technology (ABT) in January of 1994 as Director of Manufacturing Development and was promoted to Vice President in 1995. He led the team responsible for technology transfer, startup, validation, and commissioning of ABT's biopharmaceutical manufacturing plant in Smithfield, RI, and was appointed Vice President of Operations and General Manager in 1997. Mr. Galliher joined LeukoSite, Inc. in 1999 as Vice President of Biologics Manufacturing. After Millennium Pharmaceuticals acquired LeukoSite later that year, Mr. Galliher managed Millennium's worldwide biologics manufacturing operations, including leadership of the CMC Team that contributed to FDA licensure of the CAMPATH monoclonal antibody in 2001. He also led the Manufacturing Productivity Improvement program, which enabled high speed development of Millennium's anti-CCR-2 Mab for clinical trials. Mr. Galliher founded Xcellerex in December 2002.

**# # #**